- Home
- GAME vs DXR Comparison
GAME vs DXR Comparison
Compare GAME & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | DXR |
|---|---|---|
| Founded | 2011 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 66.3M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | GAME | DXR |
|---|---|---|
| Price | $0.55 | $12.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.9M | 4.3K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $102,810,388.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.44 | N/A |
| P/E Ratio | ★ N/A | $34.66 |
| Revenue Growth | ★ 188.95 | N/A |
| 52 Week Low | $0.42 | $6.55 |
| 52 Week High | $2.87 | $14.15 |
Technical Indicators
Market Signals| Indicator | GAME | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 43.47 |
| Support Level | $0.48 | $12.21 |
| Resistance Level | $0.56 | $13.02 |
| Average True Range (ATR) | 0.04 | 0.49 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 83.97 | 19.02 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.